| Not Yet Recruiting | "Efficacy and Safety of Linaclotide in Chronic Constipation" NCT07431957 | Md Mehedi Shahriar | Phase 4 |
| Not Yet Recruiting | This Study Aims to Evaluate the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Properties and Food NCT06736912 | HK inno.N Corporation | Phase 1 |
| Unknown | Evaluation of Clinical Equivalence Between Two Linaclotide Products in the Treatment of Chronic Idiopathic Con NCT04804267 | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Phase 3 |
| Completed | Efficacy and Safety of Vibrant Capsule vs. Placebo for the Treatment of Chronic Idiopathic Constipation NCT03879239 | Vibrant Ltd. | N/A |
| Completed | Efficacy and Safety of Vibrant Capsule vs. Vibrant Placebo for the Treatment of Chronic Idiopathic Constipatio NCT04458675 | Vibrant Ltd. | Phase 4 |
| Completed | A Postmarketing Study of Plecanatide in Breast Milk of Lactating Women Treated With TRULANCE® NCT03551873 | Bausch Health Americas, Inc. | — |
| Completed | Evaluation of the Bioequivalence of Sprinkle and Capsule Formulations of Lubiprostone, as Compared to Placebo NCT03097861 | Sucampo Pharma Americas, LLC | Phase 3 |
| Completed | The Effect of CSP01 on Chronic Idiopathic Constipation and Irritable Bowel Syndrome With Constipation NCT03054506 | Massachusetts General Hospital | N/A |
| Completed | An Efficacy and Safety Study of Plecanatide in Adolescents 12 to <18 Years of Age With Chronic Idiopathic Cons NCT03120520 | Bausch Health Americas, Inc. | Phase 2 |
| Completed | An Open Label Study of Chronic Use of BLI400 Laxative in Constipated Adults NCT02819310 | Braintree Laboratories | Phase 3 |
| Completed | BLI400-302: A Safety and Efficacy Evaluation of BLI400 Laxative in Constipated Adults NCT02819297 | Braintree Laboratories | Phase 3 |
| Completed | Lubiprostone for Treatment of Chronic Idiopathic Constipation NCT02695719 | Takeda | Phase 3 |
| Completed | An Open-Label, Long-term Study to Assess the Immunogenicity of LINZESS® (Linaclotide) Administered Orally to A NCT02590432 | Forest Laboratories | Phase 4 |
| Completed | A Safety and Efficacy Evaluation of BLI400 Laxative in Constipated Adults NCT02481947 | Braintree Laboratories | Phase 3 |
| Withdrawn | Elobixibat Colonic Motor Function Study NCT02392546 | Ferring Pharmaceuticals | Phase 2 |
| Completed | Trial of Linaclotide in Patients With Chronic Idiopathic Constipation NCT02291679 | Ironwood Pharmaceuticals, Inc. | Phase 3 |
| Terminated | Efficacy of Linaclotide to Senna for CIC NCT02239510 | TriHealth Inc. | N/A |
| Unknown | Botulinum Toxin Injection Versus Anal Myectomy in Management of Idiopathic Constipation NCT02361749 | Cairo University | Phase 4 |
| Completed | Performance, Efficacy and Safety of Vibrating Capsule in Aiding Constipated Individuals NCT02030756 | Vibrant Ltd. | N/A |
| Completed | 12-Week Study of Plecanatide for CIC (The National CIC3 Study) NCT02122471 | Bausch Health Americas, Inc. | Phase 3 |
| Completed | 12-Week Study of Plecanatide for CIC (The CIC3 Study) NCT01982240 | Bausch Health Americas, Inc. | Phase 3 |
| Completed | Pharmacodynamic, Pharmacokinetic, and Tolerability Study of a Liquid Form of Lubiprostone in Adult Subjects Wi NCT01993875 | Mallinckrodt | Phase 3 |
| Completed | A Multicenter, Double-Blind, Randomized, Placebo-Controlled, 12-Week, Dose-Range-Finding Trial of YKP10811 Cap NCT01989234 | SK Life Science, Inc. | Phase 2 |
| Completed | Safety and Tolerability Extension Trial for Patients With Chronic Idiopathic Constipation NCT01895543 | Ferring Pharmaceuticals | Phase 3 |
| Completed | Open-label Extension (OLE) Study of Plecanatide for Chronic Idiopathic Constipation (CIC) NCT01919697 | Bausch Health Americas, Inc. | Phase 3 |
| Terminated | 26 Week Efficacy and Safety Trial for Patients With Chronic Idiopathic Constipation NCT01827592 | Ferring Pharmaceuticals | Phase 3 |
| Terminated | Efficacy and Safety Trial of Elobixibat in Patients With Chronic Idiopathic Constipation NCT01833065 | Ferring Pharmaceuticals | Phase 3 |
| Completed | Evaluation of Clinical Equivalence Between Two Lubiprostone Products in the Treatment of Chronic Idiopathic Co NCT01674530 | Dr. Reddy's Laboratories Limited | Phase 3 |
| Completed | Lubiprostone Effect on Gastrointestinal Tract Transit Times Measured by Smartpill in Patients With Chronic Con NCT01469819 | Texas Tech University Health Sciences Center, El Paso | Phase 2 / Phase 3 |
| Completed | The Plecanatide Chronic Idiopathic Constipation (CIC) Study NCT01429987 | Bausch Health Americas, Inc. | Phase 2 / Phase 3 |
| Completed | Evaluation of Clinical Equivalence Between Two Lubiprostone Products NCT01372423 | Anchen Pharmaceuticals, Inc | Phase 3 |
| Completed | SP-304 Dose Ranging Study in Patients With Chronic Idiopathic Constipation NCT01053962 | Bausch Health Americas, Inc. | Phase 2 |
| Terminated | Domperidone for Relief of Gastrointestinal Disorders NCT00761254 | Carle Physician Group | N/A |
| Completed | Effects of Lubiprostone on Gastric Function in Patients With Chronic Idiopathic Constipation NCT01460225 | Dartmouth-Hitchcock Medical Center | Phase 4 |
| No Longer Available | A Treatment Investigational New Drug (tIND) Program of Tegaserod in Women With Irritable Bowel Syndrome With C NCT00511771 | Novartis | — |
| Completed | A Exploratory Study of KWA-0711 in Patients With Chronic Idiopathic Constipation (CIC) NCT01600001 | Kissei Pharmaceutical Co., Ltd. | Phase 2 |